Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
L-NAME raises BP with bradycardia in rats; leaves open sympathetic contribution to NOS inhibition hypertension in humans.
To determine whether increased sympathetic activity contributes to the hypertension induced by chronic exposure to moderate nitric oxide synthase (NOS) inhibition, various indexes of autonomic function were measured in rats given the NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME, 10 mg/100 ml, approximately equal to 16 mg.kg-1.day-1) in the drinking water. One week of treatment raised blood pressure (139 +/- 3 vs. 106 +/- 1 mmHg; P < 0.01) and lowered heart rate (319 +/- 4 vs. 379 +/- 6 beats/min, P < 0.01). L-NAME had no effect on cardiac sympathetic tone, but elevated cardiac parasympathetic tone (-73 +/- 4 vs. -56 +/- 7 beats/min; P < 0.05). Depressor responses to ganglionic blockade were greater in L-NAME-treated rats (-50 +/- 5 vs. -34 +/- 5 mmHg; P < 0.05), whereas resting plasma, renal, and adrenal catecholamine values did not differ between groups. Treated rats also showed evidence of reduced baroreflex sympathetic stimulation of heart rate during hypotension and reduced parasympathetic activation during hypertension. Together, these data provide only very limited, indirect evidence that sympathetic stimulation contributes to the hypertension associated with moderate NOS inhibition.
No takes yet. Share an insight, caveat, or question.
Scrogin et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: